The study was published as a preprint on researchsquare.com and has not yet been peer reviewed. Key Takeaway The response of IDH-wild type recurrent glioblastoma to vascular endothelial growth factor (VEGF) inhibitors can be predicted by the pretreatment MRI contrast enhancing pattern. With predominantly contrast enhancing lesions, bevacizumab prolongs progression-free…
bubmagJanuary 21, 2022